News from abbvie A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

May 16, 2022, 08:00 ET AbbVie to Showcase Depth of Gastroenterology Portfolio and Pipeline at Digestive Disease Week®

AbbVie (NYSE: ABBV) today announced that 27 abstracts across its gastroenterology portfolio will be presented at the Digestive Disease Week (DDW)...

May 16, 2022, 07:30 ET AbbVie and Cugene Announce Collaboration in Autoimmune Diseases

AbbVie (NYSE: ABBV) and Cugene Inc., a clinical-stage biotechnology company focused on developing next-generation precision immunology and oncology...

May 12, 2022, 11:39 ET AbbVie to Showcase Oncology Portfolio and Pipeline During the 2022 ASCO and EHA Annual Congresses

AbbVie (NYSE: ABBV) will present 46 abstracts across eight types of cancer during the upcoming American Society of Clinical Oncology (ASCO) Annual...

May 12, 2022, 08:30 ET AbbVie Awards 45 Scholarships to U.S. Students Living with Chronic, Immune-Mediated Diseases in Their Pursuit of Higher Education

AbbVie today announced the 2022-2023 class of recipients of the AbbVie Immunology Scholarship, which provides financial support to students living...

May 11, 2022, 08:45 ET Upadacitinib (RINVOQ®) Achieved Clinical Remission and Endoscopic Response at One Year in Phase 3 Maintenance Study in Patients with Crohn's Disease

In patients with moderate to severe Crohn's disease who achieved clinical response to upadacitinib induction treatment, a significantly greater...

Apr 29, 2022, 14:44 ET RINVOQ® (upadacitinib) Approved by U.S. FDA as an Oral Treatment for Adults with Active Ankylosing Spondylitis

AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) has approved RINVOQ® (upadacitinib; 15 mg, once daily) for the...

Apr 29, 2022, 07:43 ET AbbVie Reports First-Quarter 2022 Financial Results

Reports First-Quarter Diluted EPS of $2.51 on a GAAP Basis, an Increase of 26.1 Percent; Adjusted Diluted EPS of $3.16, an Increase of 9.3 Percent;...

Apr 28, 2022, 08:30 ET Allergan, an AbbVie Company, to Present New Data from its Leading Portfolio of Eye Care Treatments at the 2022 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting

Allergan, an AbbVie (NYSE: ABBV) company, announced that it will present new data on VUITY™ (pilocarpine HCl ophthalmic solution) 1.25%, the first...

Apr 19, 2022, 08:30 ET Allergan, an AbbVie Company, to Present New Data from its Eye Care Portfolio at the 2022 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting

Allergan, an AbbVie (NYSE: ABBV) company, announced that it will present new data from its leading eye care portfolio at the 2022 American Society...

Apr 14, 2022, 08:00 ET AbbVie to Host First-Quarter 2022 Earnings Conference Call

AbbVie (NYSE: ABBV) will announce its first-quarter 2022 financial results on Friday, April 29, 2022, before the market opens. AbbVie will host a...

Apr 13, 2022, 18:53 ET AbbVie and Genmab Announce Topline Results for Epcoritamab (DuoBody®-CD3xCD20) from Phase 1/2 Trial in Patients with Relapsed/Refractory Large B-cell Lymphoma (LBCL)

AbbVie (NYSE: ABBV) and Genmab A/S (Nasdaq: GMAB) today announced topline results from the first cohort of the EPCORE™ NHL-1 phase 1/2 clinical trial ...

Apr 13, 2022, 11:00 ET AbbVie Celebrates 30th Anniversary of CF Scholarship with Opening of Application Period for Students with Cystic Fibrosis

AbbVie today announced that the AbbVie Cystic Fibrosis (CF) Scholarship program is now accepting applications for the 2022-2023 academic school year. ...
BOTOX® Cosmetic (onabotulinumtoxinA) Celebrates 20 Years Since First U.S. FDA Approval

Apr 13, 2022, 08:00 ET BOTOX® Cosmetic (onabotulinumtoxinA) Celebrates 20 Years Since First U.S. FDA Approval

Allergan Aesthetics, an AbbVie company (NYSE: ABBV), announces the celebration of a milestone moment for BOTOX® Cosmetic (onabotulinumtoxinA). April...

Apr 12, 2022, 08:00 ET AbbVie Presents Positive Investigational Navitoclax Combination Data in Phase 2 REFINE Study Suggesting Anti-Fibrosis Activity for Patients with Myelofibrosis

- Navitoclax is being studied in myelofibrosis, a rare, difficult-to-treat blood cancer - Results are from an exploratory analysis of 34...

Apr 05, 2022, 08:30 ET Allergan, an AbbVie Company, Announces Positive Topline Phase 3 Results Evaluating Investigational Twice-Daily Administration of VUITY™ (pilocarpine HCI ophthalmic solution) 1.25% in Adults with Age-Related Blurry Near Vision (Presbyopia)

VUITY is the first and only eye drop to treat presbyopia, or age-related blurry near vision, in adults and is FDA-approved for once-daily...

Mar 29, 2022, 08:00 ET AbbVie to Showcase Breadth of Neuroscience Portfolio and Pipeline at American Academy of Neurology (AAN) 2022 Annual Meeting

AbbVie (NYSE: ABBV) today announced that data from its neuroscience portfolio will be presented at the 2022 American Academy of Neurology (AAN)...

Mar 29, 2022, 03:01 ET ALLERGAN AESTHETICS BRINGS DATA, INNOVATION & INDUSTRY EXPERTISE TO THE 2022 AESTHETIC AND ANTI-AGING MEDICINE WORLD CONGRESS (AMWC)

Allergan Aesthetics, an AbbVie company, will join industry colleagues and healthcare providers from around the globe for the 20th edition of AMWC in...

Mar 21, 2022, 08:30 ET AbbVie and Allergan Aesthetics to Present New Research Across Dermatology Portfolio at 2022 AAD Annual Meeting

AbbVie (NYSE: ABBV) and Allergan Aesthetics, an AbbVie company, today announced they will present 12 abstracts and two late-breaking presentations...

Mar 16, 2022, 17:29 ET RINVOQ® (upadacitinib) Receives FDA Approval for the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis

In clinical trials, RINVOQ (upadacitinib) achieved the primary endpoints of clinical remission (per modified Mayo Score [mMS]) at weeks 8 and 521-4 A ...

Mar 15, 2022, 08:45 ET Now Available Over the Counter, LASTACAFT® Provides Eye Allergy Itch Relief in Minutes that Lasts Through 16 Hours

Allergan, an AbbVie (NYSE: ABBV) company, today announced that LASTACAFT® (alcaftadine ophthalmic solution 0.25%) is now available without a...

Mar 15, 2022, 08:00 ET AbbVie and Scripps Research Announce Collaboration to Develop Antiviral Treatments for COVID-19

AbbVie (NYSE: ABBV) and Scripps Research, an independent, non-profit biomedical research and drug discovery institute, today announced a global...

Mar 11, 2022, 02:00 ET AbbVie and Gedeon Richter Announce Collaboration in Neuropsychiatric Diseases

AbbVie (NYSE: ABBV) and Gedeon Richter Plc. ('Richter') today announced a new co-development and license agreement to research, develop and...

Mar 10, 2022, 08:15 ET AbbVie Announces Positive Phase 3 Atogepant (QULIPTA™) Data for the Preventive Treatment of Chronic Migraine

AbbVie (NYSE: ABBV) today announced that the Phase 3 PROGRESS trial evaluating atogepant (QULIPTA™ in the United States), an oral calcitonin...

Mar 08, 2022, 16:32 ET AbbVie Resolves HUMIRA® (adalimumab) U.S. Litigation with Alvotech

AbbVie (NYSE: ABBV) announced that it has resolved all U.S. HUMIRA (adalimumab) litigation with Alvotech. Under the terms of the resolution, AbbVie...

Mar 01, 2022, 08:30 ET AbbVie to Present at the Cowen 42nd Annual Health Care Conference

AbbVie (NYSE: ABBV) will participate in the Cowen 42nd Annual Health Care Conference on Tuesday, March 8, 2021. Robert A. Michael, vice chairman,...